Kyverna Therapeutics Inc (KYTX) Stock Price, Quote & News

Company Profile

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; a...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 925 2492

Website: kyvernatx.com

Address:

5980 Horton Street, Suite 550, Emeryville, United States

kkorotney Feb. 4 at 5:32 AM

$KYTX https://x.com/i/status/2018908751068008794

0 · Reply

Th3M4skedSt0nker Feb. 3 at 7:48 PM

$KYTX

0 · Reply

kellymone2 Feb. 3 at 1:45 PM

$KYTX https://ir.kyvernatx.com/news-releases/news-release-details/kyverna-therapeutics-appoints-mayo-pujols-chief-technology "Mr. Pujols brings more than 30 years of technical operations experience to the role with a deep background in leading late-stage and commercial manufacturing for cell and gene therapies. His work spans both large-scale and smaller biopharmaceutical companies with a proven track record of successfully advancing programs across their lifecycles." KYTX is ready

2 · Reply

Madmortigan Feb. 2 at 3:40 PM

$KYTX are we back?

1 · Reply

Madmortigan Feb. 1 at 6:10 PM

$KYTX $7.50 tomorrow? 🤦‍♂️

2 · Reply

PeterMarksMD Jan. 30 at 4:24 PM

$KYTX Back to offering

0 · Reply

Madmortigan Jan. 30 at 4:23 PM

$KYTX

0 · Reply

Roaring_Capybara Jan. 30 at 3:45 PM

$KYTX Added 1K shares 7.70

1 · Reply

bernardbaruch Jan. 30 at 3:07 PM

$KYTX scale bot 1000 on the day at $7.91 avg to hold 3000, short 10 Feb 26 $10 calls @$0.45 I really like the entry at these levels -The $7.50 per share $100MM+ equity print from mid Dec? has had six volatile weeks to breach ( on volume) and it hasn’t. -minimal ST followers/retail buzz a positive imo - low end of the trading range for a 25% swing -Clean narrative for a take out 2026 /2027 - Great visibility on Celine Dion “stiff person syndrome” -robust pipeline What could go wrong?? JK it’s a bio, everything could go wrong NIA

0 · Reply

Baldchinese Jan. 30 at 2:43 PM

$KYTX sub 8 today it seems. Just has zero strenght these past days sadly

0 · Reply

Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer

Jan 12, 2026, 8:00 AM EST - 22 days ago

Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference

Jan 5, 2026, 8:00 AM EST - 4 weeks ago

Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference

Dec 18, 2025, 2:48 PM EST - 6 weeks ago

Kyverna Therapeutics: Taking The Next Step In Autoimmune Cell Therapies

Dec 17, 2025, 11:59 AM EST - 6 weeks ago

Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data From KYSA-8 Trial of Miv-cel in Stiff Person Syndrome Transcript

Dec 17, 2025, 9:24 AM EST - 6 weeks ago

Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock

Dec 16, 2025, 3:46 PM EST - 7 weeks ago

Kyverna Therapeutics: "Strong Buy" Rating As Positive SPS Data Leads To 1st Half 2026 BLA Filing

Dec 16, 2025, 8:06 AM EST - 7 weeks ago

Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

LWLG

Dec 15, 2025, 4:01 PM EST - 7 weeks ago

Kyverna Therapeutics Announces Proposed Public Offering of Common Stock

Dec 15, 2025, 12:06 PM EST - 7 weeks ago

Kyverna Therapeutics: Miv-Cel Delivers Breakthrough Data In Stiff Person Syndrome

Dec 15, 2025, 6:42 AM EST - 7 weeks ago

Kyverna's cell therapy meets main goal of mid-stage study

Dec 15, 2025, 6:30 AM EST - 7 weeks ago

Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome

Dec 14, 2025, 2:30 PM EST - 7 weeks ago

Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

Dec 8, 2025, 9:00 AM EST - 2 months ago

Stock Picks From Seeking Alpha's November 2025 New Analysts

ABEV CEG CEPU EAT GLXY GT KOF

Nov 14, 2025, 2:24 AM EST - 2 months ago

Kyverna Therapeutics: Immune Reset Is Clinically Validated, Market Ignores Potential

Nov 12, 2025, 4:05 PM EST - 2 months ago

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 8:00 AM EST - 3 months ago

Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 3, 2025, 8:00 AM EST - 3 months ago

Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance

Oct 29, 2025, 6:30 AM EDT - 3 months ago

Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025

Oct 25, 2025, 11:00 AM EDT - 3 months ago

Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025

Oct 22, 2025, 8:00 AM EDT - 3 months ago

Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis

Sep 24, 2025, 9:05 AM EDT - 4 months ago

Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS

Sep 15, 2025, 1:02 PM EDT - 5 months ago

Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025

Aug 28, 2025, 8:00 AM EDT - 5 months ago

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

Aug 25, 2025, 4:02 PM EDT - 5 months ago

Kyverna Therapeutics to Present at Upcoming Investor Conferences in September

Aug 20, 2025, 3:29 PM EDT - 5 months ago

Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026

Aug 12, 2025, 4:02 PM EDT - 6 months ago

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Jul 29, 2025, 8:30 AM EDT - 6 months ago

Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise

May 28, 2025, 4:02 PM EDT - 8 months ago

Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference

May 27, 2025, 3:42 PM EDT - 9 months ago

With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around?

May 13, 2025, 4:02 PM EDT - 9 months ago

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Mar 27, 2025, 4:02 PM EDT - 11 months ago

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 21, 2025, 11:29 AM EDT - 11 months ago

Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025

Mar 3, 2025, 4:05 PM EST - 1 year ago

Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Feb 7, 2025, 11:42 AM EST - 1 year ago

KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

Feb 6, 2025, 1:51 PM EST - 1 year ago

Investors in Kyverna Therapeutics, Inc. Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights – KYTX

Feb 5, 2025, 11:54 AM EST - 1 year ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics

kkorotney Feb. 4 at 5:32 AM

$KYTX https://x.com/i/status/2018908751068008794

0 · Reply

Th3M4skedSt0nker Feb. 3 at 7:48 PM

$KYTX

0 · Reply

kellymone2 Feb. 3 at 1:45 PM

2 · Reply

Madmortigan Feb. 2 at 3:40 PM

$KYTX are we back?

1 · Reply

Madmortigan Feb. 1 at 6:10 PM

$KYTX $7.50 tomorrow? 🤦‍♂️

2 · Reply

PeterMarksMD Jan. 30 at 4:24 PM

$KYTX Back to offering

0 · Reply

Madmortigan Jan. 30 at 4:23 PM

$KYTX

0 · Reply

Roaring_Capybara Jan. 30 at 3:45 PM

$KYTX Added 1K shares 7.70

1 · Reply

bernardbaruch Jan. 30 at 3:07 PM

0 · Reply

Baldchinese Jan. 30 at 2:43 PM

$KYTX sub 8 today it seems. Just has zero strenght these past days sadly

0 · Reply

SqueezeChamber Jan. 30 at 2:07 PM

$KYTX Signals remain inconclusive

0 · Reply

Merlintrader Jan. 30 at 1:42 PM

$KYTX https://www.merlintrader.com/kytx-kyverna-therapeutics-inc/

1 · Reply

rispi Jan. 30 at 10:32 AM

@Merlintrader hi, I'm considering investing in $FBIO $RCKT $TLSA $KYTX Have you already published any DD about one of those? Right now I don't have any open position yet. thanks

3 · Reply

Madmortigan Jan. 29 at 8:04 PM

$KYTX just out of curiousity - how long do insiders have before they have to disclose their buying or selling?

1 · Reply

Madmortigan Jan. 29 at 2:58 PM

$KYTX

0 · Reply

Baldchinese Jan. 29 at 2:56 PM

$KYTX rough week here. Even with $XBI green we cant seem to stop tanking. Hopefully next week is better

0 · Reply

BiodegradableBurger Jan. 29 at 2:42 PM

$KYTX Da fuq?! Last week we were $10.50 jfc.

0 · Reply

Madmortigan Jan. 28 at 10:42 PM

$KYTX I can’t buy the dip when my kids are eating bologna sandwiches bc I went all in around 9.00!!!

0 · Reply

Roaring_Capybara Jan. 28 at 9:18 PM

$KYTX YES I did!!! .... add 2000 at $8.35. We've got "Anti-Stiff" with millions waiting for relief. No Brainer.

1 · Reply

Baldchinese Jan. 28 at 8:10 PM

$KYTX damn we getting nuked over here

0 · Reply

Madmortigan Jan. 28 at 6:32 PM

$KYTX Is the uptrend over? 🤦‍♂️

2 · Reply

bernardbaruch Jan. 28 at 3:18 PM

$KYTX bot 1000 $8.75

1 · Reply

Market Cap	350.81M
Revenue (ttm)	0.00
Net Income (ttm)	-127.48M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	658,100
Avg Vol	1,645,636
Day's Range	N/A - N/A
Shares Out	43.80M
Stochastic %K	23%
Beta	3.45
Analysts	Strong Sell
Price Target	$28.20